Rahul Khara Sells 5,000 Shares of Disc Medicine (NASDAQ:IRON) Stock

Disc Medicine, Inc. (NASDAQ:IRON) insider Rahul Khara sold 5,000 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $80.00, for a total value of $400,000.00. Following the completion of the sale, the insider directly owned 52,324 shares in the company, valued at approximately $4,185,920. The trade was a 8.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Rahul Khara also recently made the following trade(s):

• On Friday, June 26th, Rahul Khara sold 851 shares of Disc Medicine stock. The shares were sold at an average price of $75.00, for a total transaction of $63,825.00.
• On Monday, June 29th, Rahul Khara sold 1,649 shares of Disc Medicine stock. The stock was sold at an average price of $75.00, for a total value of $123,675.00.
• On Thursday, June 18th, Rahul Khara sold 7,500 shares of Disc Medicine stock. The stock was sold at an average price of $70.22, for a total transaction of $526,650.00.

Disc Medicine Stock Performance

IRON stock opened at $77.44 on Friday. The company has a quick ratio of 24.14, a current ratio of 24.14 and a debt-to-equity ratio of 0.09. The company has a market cap of $2.96 billion, a price-to-earnings ratio of -11.77 and a beta of 1.00. The business has a fifty day simple moving average of $73.59 and a 200-day simple moving average of $69.79. Disc Medicine, Inc. has a 52 week low of $40.00 and a 52 week high of $99.50.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, beating the consensus estimate of ($1.71) by $0.17. On average, equities research analysts expect that Disc Medicine, Inc. will post -6.61 EPS for the current year.

Trending Headlines about Disc Medicine

Here are the key news stories impacting Disc Medicine this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and raised its price target to $120. The target is well above the stock’s recent trading level, signaling substantial expected upside if Disc Medicine’s clinical and commercial plans progress. HC Wainwright analyst estimates
• Positive Sentiment: HC Wainwright modestly improved its EPS forecasts for fiscal 2026, the fourth quarter of 2026 and fiscal 2028. Although the company is expected to remain unprofitable in those periods, the revisions indicate slightly better projected results. The firm expects earnings to turn positive in 2029.
• Neutral Sentiment: The analyst’s estimates were mixed overall: forecasts improved for some periods but were lowered for fiscal 2027, 2029 and 2030. The changes were small and did not alter the firm’s bullish rating or $120 target, suggesting limited immediate impact on valuation expectations.
• Negative Sentiment: Rosen Law Firm said it is investigating potential securities claims on behalf of Disc Medicine shareholders over allegations that the company may have issued materially misleading business information. The announcement does not establish wrongdoing or confirm that a lawsuit will be filed, but it could increase legal costs and investor uncertainty. Rosen Law Firm investigation notice
• Negative Sentiment: Insider Rahul Khara sold 5,000 shares for approximately $400,000, reducing his ownership by 8.72%. He still holds 52,324 shares, so the transaction does not necessarily indicate a change in company fundamentals, but repeated insider selling can pressure investor sentiment. SEC insider filing

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on IRON shares. Wedbush reaffirmed an “outperform” rating and issued a $88.00 target price on shares of Disc Medicine in a research report on Wednesday, June 10th. Wall Street Zen raised shares of Disc Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, August 1st. HC Wainwright upped their price target on shares of Disc Medicine from $118.00 to $120.00 and gave the company a “buy” rating in a report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Disc Medicine in a research note on Friday, July 17th. Finally, Morgan Stanley raised their price objective on shares of Disc Medicine from $80.00 to $85.00 and gave the stock an “overweight” rating in a report on Monday, June 15th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $106.00.

Institutional Trading of Disc Medicine

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. acquired a new stake in Disc Medicine in the 2nd quarter valued at about $180,502,000. RA Capital Management L.P. boosted its holdings in Disc Medicine by 25.3% during the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock worth $156,925,000 after buying an additional 399,026 shares in the last quarter. Vanguard Group Inc. grew its position in Disc Medicine by 22.1% in the fourth quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company’s stock worth $140,371,000 after buying an additional 319,621 shares during the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Disc Medicine by 28.0% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company’s stock valued at $134,839,000 after acquiring an additional 371,576 shares during the last quarter. Finally, JPMorgan Chase & Co. boosted its stake in shares of Disc Medicine by 110.0% during the 4th quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock worth $125,557,000 after acquiring an additional 828,248 shares in the last quarter. 83.70% of the stock is currently owned by institutional investors.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.